Literature DB >> 1367404

A comparison of serum-free media for the support of in vitro mitogen-induced blastogenic expansion of cytolytic lymphocytes.

D W McVicar1, F Li, C W McCrady, R E Merchant.   

Abstract

The high cost and potential dangers of including human AB serum in incubation media used to expand lymphocyte populations in vitro for adoptive immunotherapy have stimulated efforts to develop defined media which can support both the expansion and induction of lymphocytes with tumor cytolytic activity in the absence of serum. Lymphocyte proliferation following exposure to either PHA or the combination of phorbol 12,13-dibutyrate (PDBu) and the calcium ionophore, ionomycin, was evaluated. Although the media tested, X-Vivo 10, HB-104, AIM V, and HL-1, supported the generation of comparable levels of LAK activity after 3-5 days incubation with 10(3) U human recombinant interleukin-2 (rIL-2)/ml, there were striking differences in the ability of each medium to support mitogenically stimulated lymphocytes in the absence of serum, with cells in AIM V and X-Vivo 10 showing the highest levels of DNA synthesis. In long-term cultures (17 days) of blood MNC stimulated by PDBu and ionomycin, X-Vivo 10 and HB-104 yielded the greatest numbers of cells. The addition of 2% AB serum greatly enhanced the ability of each medium to support cell proliferation to equivalent maximum levels. The results indicate that while all four serum-free media were suitable for lymphocyte culture and support the development of LAK activity, they differ in their capacity to support expansion of lymphocyte populations in response to polyclonal mitogenic activation. This latter characteristic should be considered before choosing a particular serum-free formulation as its constituents may affect mechanistic interpretations regarding signal transduction events.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1367404     DOI: 10.1007/bf00373027

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  8 in total

1.  The generation of human lymphokine-activated killer cells in various serum-free media.

Authors:  M R Jadus; G B Thurman; A Mrowca-Bastin; J R Yannelli
Journal:  J Immunol Methods       Date:  1988-05-09       Impact factor: 2.303

Review 2.  Inositol trisphosphate and diacylglycerol as second messengers.

Authors:  M J Berridge
Journal:  Biochem J       Date:  1984-06-01       Impact factor: 3.857

3.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

4.  Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors.

Authors:  S K Beckner; A E Maluish; D L Longo
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

5.  Induction of lymphokine activated killer cells in serum-free medium.

Authors:  C J Froelich; S Guiffaut
Journal:  J Immunol Methods       Date:  1986-02-12       Impact factor: 2.303

6.  A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

Authors:  R J Melder; T L Whiteside; N L Vujanovic; J C Hiserodt; R B Herberman
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

7.  Alteration of human lymphokine-activated killer cell activity by manipulation of protein kinase C and cytosolic Ca2+.

Authors:  C W McCrady; F Li; A J Grant; R E Merchant; R A Carchman
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

8.  Studies of serum-free culture medium in the generation of lymphokine activated killer cells.

Authors:  L M Muul; K Nason-Burchenal; C Hyatt; S Schwarz; D Slavin; E P Director; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-12-24       Impact factor: 2.303

  8 in total
  1 in total

1.  Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.

Authors:  Andrew R Medvec; Christopher Ecker; Hong Kong; Emily A Winters; Joshua Glover; Angel Varela-Rohena; James L Riley
Journal:  Mol Ther Methods Clin Dev       Date:  2017-11-07       Impact factor: 6.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.